What’s Better Than Ozempic to Lose Weight? Exploring Effective Alternatives

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The question contains a false premise worth clearing up first: Ozempic is not an FDA-approved weight-loss medication, so almost anything approved for weight management is a different category rather than a "better" version of it. The Ozempic label carries three indications, all in type 2 diabetes — glycemic control, cardiovascular risk reduction in established cardiovascular disease, and cardiorenal risk reduction in chronic kidney disease. If weight reduction is your goal, the meaningful comparison is between the products the FDA has actually approved for that purpose: Wegovy, Zepbound, and the newer oral option approved in 2026. Those have real head-to-head data behind them, and this article walks through what that data shows.

Wegovy: The Semaglutide Product Approved for Weight

Wegovy and Ozempic contain the same molecule but hold different approvals. Per the Wegovy prescribing information, Wegovy injection is indicated, with a reduced-calorie diet and increased physical activity, for weight reduction in adults and pediatric patients 12 years and older with obesity, for weight reduction in adults with overweight plus at least one weight-related condition, for reducing major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and — under accelerated approval — for treating noncirrhotic MASH with moderate-to-advanced liver fibrosis.

The evidence anchor is STEP 1: a 68-week trial in 1,961 adults reporting mean weight change of −14.9% with semaglutide 2.4 mg versus −2.4% with placebo, with 86.4% of participants reaching at least a 5% reduction. Wegovy's labeled range has since extended upward, with a 7.2 mg strength added when Wegovy HD was approved in March 2026.

Wegovy tablets, approved in December 2025, sit within the same label. They carry two of the injection's indications — weight reduction and cardiovascular risk reduction — and not the pediatric or MASH indications.

Zepbound: The Head-to-Head Winner in the Published Comparison

Zepbound contains tirzepatide and is approved for reducing excess body weight and maintaining weight reduction long term in adults with obesity or overweight with a weight-related comorbid condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity.

The comparison people actually want was published in 2025. SURMOUNT-5 was a phase 3b open-label trial that randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide or the maximum tolerated dose of semaglutide once weekly for 72 weeks. Least-squares mean percent weight change at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide. Mean waist circumference change was −18.4 cm versus −13.0 cm. Participants on tirzepatide were more likely to reach reductions of at least 10%, 15%, 20%, and 25%.

That is a direct, randomized comparison — the strongest form of evidence available on this question. It also has limits: it was open-label, it excluded people with type 2 diabetes, and it compared maximum tolerated doses rather than fixed ones. Superiority on a population average does not mean superiority for every individual.

Orforglipron: The First Oral Small-Molecule Option

The newest entry changes the format rather than the mechanism. Orforglipron, marketed as Foundayo, was approved on April 1, 2026, and is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition.

It is supplied as tablets in six strengths — 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg. Like the injectables, it carries a boxed warning tied to thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in those with known serious hypersensitivity to the drug or its excipients.

For people whose objection to treatment is the injection itself, an oral option is genuinely new. Whether it is the right option is a different question, and one that depends on the same clinical factors as any other.

What "Better" Should Actually Mean

Average percent weight loss is one axis, and it is the one marketing fixates on. It is not the only one. Tolerability matters — gastrointestinal adverse events were the most common in every one of these programs, and were most frequent during dose escalation. Coexisting conditions matter: if you have established cardiovascular disease, an indication for cardiovascular risk reduction may weigh more than a few percentage points of average weight change. If you have moderate-to-severe obstructive sleep apnea with obesity, one product holds a specific approval for it.

Contraindications matter most of all, and they are shared across this class: a personal or family history of medullary thyroid carcinoma or MEN 2, and prior serious hypersensitivity to the specific molecule. Every one of these labels also states that weight loss offers no benefit during pregnancy and may cause fetal harm.

Route, dosing frequency, and what you will realistically sustain for a year also belong in the comparison. A superior average in a trial is not superior if it is not the treatment you can stay on.

What Compounded Products Are — and Are Not

Compounded semaglutide and compounded tirzepatide are not FDA-approved finished products. The FDA does not review compounded preparations for safety, effectiveness, or quality before they are marketed, and no compounded preparation is a generic version of Wegovy, Ozempic, Zepbound, or Mounjaro — none of those has an approved generic. The FDA's compounding enforcement discretion periods closed in February and March 2025 for tirzepatide and in April and May 2025 for semaglutide.

What compounding does is allow a licensed pharmacy to prepare a medication pursuant to a prescription written for an individual patient. That is a legitimate, regulated pathway, and it is materially different from products sold directly to consumers as research chemicals. The trial figures cited above describe the branded products those trials studied, and should not be read as claims about any compounded preparation.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is anything actually better than Ozempic for weight loss?

The premise needs correcting first: Ozempic is not approved for weight loss. Its label covers three type 2 diabetes indications only. The FDA-approved options for chronic weight management include Wegovy, Zepbound, and orforglipron tablets, each supported by trials with weight as the primary endpoint. Comparing them to Ozempic compares products built for different purposes.

What did the head-to-head trial between tirzepatide and semaglutide show?

SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide or semaglutide for 72 weeks. Least-squares mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide, and waist circumference change was −18.4 cm versus −13.0 cm. The trial was open-label and compared maximum tolerated doses rather than fixed doses.

Is there an FDA-approved pill for weight management?

Yes. Orforglipron, marketed as Foundayo, was approved on April 1, 2026 for reducing excess body weight and maintaining weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition, alongside a reduced-calorie diet and increased physical activity. Wegovy tablets, approved in December 2025, are another oral option within the Wegovy label.

Do all of these medications share the same safety warnings?

They share several. Each carries a boxed warning tied to thyroid C-cell tumors observed in rodents, and each is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in those with serious hypersensitivity to the drug or its excipients. Their labels also state that weight loss may cause fetal harm during pregnancy.

Are compounded versions equivalent to the approved brands?

No. Compounded semaglutide and tirzepatide are not FDA-approved finished products, and the FDA does not review them for safety, effectiveness, or quality before marketing. They are not generic versions of any approved brand, since none of these brands has an approved generic. Compounded preparations are dispensed by a licensed pharmacy pursuant to a prescription for an individual patient.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.